Xen 45 microstent a reasonable alternative for refractory glaucoma

xen-45-microstent-a-reasonable-alternative-for-refractory-glaucoma.jpg

JAN 18, 2018

Glaucoma


In this multicenter study, investigators evaluated the performance and safety of the Xen 45 ab interno gelatin stent (Allergan) for refractory glaucoma through a 12-month follow-up period.

Study design

The single-arm, open-label clinical trial enrolled 65 patients who experienced a failed filtering or cilioablative procedure (84.6%), or uncontrolled IOP (20–35 mm Hg) on maximum medical treatment (15.4%). They were followed for 12 months after stent implantation.

Outcomes

Approximately 76% of the patients had IOP reductions of at least 20% compared with baseline, on the same or fewer medications. The average drop in IOP was 6.4 mm Hg, and patients were on 2 fewer IOP-lowering medications than they were at baseline. Almost 40% of patients did not require IOP lowering medications following stent placement.

No intraoperative or unexpected postoperative complications were reported. Additional surgical intervention was required in 13.8% of patients due to uncontrolled IOP. About 15% of patients lost an average of 2 lines of vision, which self-resolved in 81% of this subgroup. Other postop complications included transient hypotony (24.6%) and IOP increase of greater than 10 mm Hg (21.5 %).

Limitations

The high percentage of patients who required at least 1 bleb needling (32.3%) may stem from conjunctival dissection prior to sponge application of MMC. The authors were unable to use a subconjunctival MMC injection as it is not FDA approved. There were no comparative arms for the intervention.

Clinical significance

The Xen can be used in refractory glaucoma in the face of failed prior surgery with good results and low complication rates at 12 months. Unlike the iStent or Cypass, it can also be used without cataract surgery.

View Abstract American Journal of Ophthalmology, November 2017

https://www.aao.org/editors-choice/xen-45-microstent-reasonable-alternative-refractor

Comments

Post a Comment

Popular posts from this blog

I Spy a Stye in Your Eye

Image
Written by Dr. David Evans Last modified on August 6, 2018 What’s that small, red, pimple-like bump on your eyelid that’s causing so much discomfort? It’s probably a stye (sometimes referred to as a sty or hordeolum). Besides being difficult to say 5 times quickly, an eye stye is a type of localized infection that can occur along the base of your eyelashes or underneath your eyelid. Styes that form along the base of the eyelashes are called external styes. They typically occur as a result of an infected eyelash hair follicle and look like the type of pimple that occurs when your pores are clogged with dirt and oil. Styes that form inside the eyelid are called internal styes. Similar to external styes, they are caused by an infection of an oil-producing gland behind the eyelid rather than an eyelash hair follicle. Internal styes result in generalized swelling of the eyelid rather than forming a pimple-like bump. Stye Symptoms As a stye develops, you might begin to experience pain
Read more

Post-LASIK Refraction and Pregnancy – Much Ado About Nothing?

Image
Written by Dr. David Evans Last modified on August 23, 2018 During pregnancy, women experience a drastic shift in their hormonal balance that has a ripple effect throughout the body. The spike in hormones like progesterone, estrogen, prolactin, oxytocin and relaxin are all important for a healthy pregnancy, but these increased levels can also impact gastrointestinal processes, blood pressure, skin pigmentation and, you guessed it, ocular health. Due to refractive changes that often occur during pregnancy, most refractive surgeons advise against LASIK during pregnancy, instead suggesting women wait several months after giving birth before considering treatment. Women who have already undergone LASIK may then wonder if the changes in ocular health that can occur during and after pregnancy impact post-LASIK refraction. New research presented by John Kanellopoulos, MD, New York University Medical School, NY, and LaserVision.gr seems to throw cold water on any such concern. The Eyes an
Read more